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Summary The combination of high-dose folinic acid with 5-fluorouracil has shown improved response rates
in several trials in advanced colorectal carcinoma. This however is at the expense of increased toxicity:
regimens using weekly bolus injections produce diarrhoea in most patients and occasional toxic deaths from
this, whilst those using daily injections for one week in four report both diarrhoea and severe oral mucositis.
Both types of regimen have significant rates of myelosuppression.
A recent report described a different schedule of 5-fluorouracil and folinic acid, which appeared better
tolerated but equally active (De Gramont et al., 1988). Here we report results using the same programme, in
64 patients with advanced adenocarcinomas. (Forty three colorectal, ten gastric, six pancreatic and five of
unknown primary.)
Patients received 200mg m2 folinic acid by infusion over 2 h followed by an IV bolus of 5-fluorouracil
400 mg m-2 then an infusion of 5-fluorouracil 400 mg m-2 over 22 h. This was repeated over the next 24 h.
The schedule was given every 2 weeks for a total of six to 12 courses depending upon the response. The overall
response rate was 26% in 62 evaluable patients.
No toxicity greater than WHO Grade II occurred. Diarrhoea and mucositis did occur in around 10% of
treatments but were not troublesome. No febrile neutropenic episodes were seen.
Despite previous reports which described only modest activity for this combination against stomach cancers,
this regimen demonstrates low toxicity but retains good activity in the palliative treatment of both gastric and
colonic adenocarcinomas.
Several trials have recently demonstrated that the administra-
tion of high-dose folinic acid can enhance the efficacy of
5-fluorouracil used in the treatment of advanced adenocar-
cinomas of gastrointestinal origin: phase III studies have
shown improved response rates and survival in colorectal
cancer (Erlichman et al., 1988; Petrelli et al., 1988; Poon et
al., 1989) although gastric cancer has been less widely stud-
ied. One phase II trial showed a response rate of 48%
(Machover et al., 1986) but another only 12% (Arbuck et al.,
1987) and a third 24% (Berenberg et al., 1989). These reports
also describe toxicity different from that produced by 5-
fluorouracil alone: Regimens using weekly bolus injections
are reported as frequently causing diarrhoea (in 22-80% of
patients) with occasional toxic deaths from this (Petrelli et
al., 1988; Petrelli et al., 1989), whilst those employing daily
injections for one week in four report both diarrhoea and
oral mucositis - the latter in 40-80% of patients (Machover
et al., 1986; Erlichman et al., 1988; Poon et al., 1989). Both
types of regimen show significant rates of myelosuppression
with neutropenia in 10-50% of patients.
A recent report (De Gramont et al., 1988) described a
regimen of short infusions of folinic acid followed by a
5-fluorouracil bolus loading dose then continuous infusion
for 48 h every 2 weeks, which appeared much better tolerated
but equally active. It has previously been suggested that
continuous infusions of 5-fluorouracil may be superior in the
treatment of colo-rectal cancer (Siefert et al., 1975; Lokich et
al., 1989) and phase I trials showed the maximum tolerated
dose to be up to four times greater if a continuous infusion is
used rather than repeated bolus doses (Lokich et al., 1981).
The cytotoxicity of 5-fluorouracil shows a steep dose-re-
sponse relationship so that the use of continuous infusions to
increase the maximum tolerated dose may be expected to
improve response rate relative to toxicity. A phase II study
was therefore undertaken using the same programme, but
also incorporating allopurinol mouthwashes with the inten-
tion to reduce oral toxicity as reported previously (Clark &
Slevin, 1985).
Patients and methods
Sixty-four patients with advanced adenocarcinomas were
treated. Four patients received adjuvant treatment following
resection of locally-advanced colonic adenocarcinomas and
are included in the toxicity analyses. The median age was 54
years (Range 18 to 77). Thirty-eight per cent were female.
The Mean Karnofsky score at the start of treatment was 75
(Range 30 to 90).
The tumour types were: colorectal 47, gastric ten, pan-
creatic six, unknown primary five. All patients' histology was
reviewed at this centre prior to the start of chemotherapy.
Twenty-two (32%) had inoperable locally-advanced or recur-
rent tumours, 53 (78%) had metastatic disease: 46 (68%)
hepatic, nine (13%) pulmonary, 11 (16%) lymphatic, seven
(10%) bony. Sixteen patients (23%) had tumour masses of
over 10cm maximum diameter. In 26 (38%) cases the size
was between 5 and 10cm and in 18 (26%) between 1 and 5
cm. The remaining eight patients had minimal disease masses
of less than 1 cm.
Chemotherapy
The treatment was given as: Folinic acid 200 mg m-2 by
IV infusion over 2 h in 5% Dextrose, then 5-Fluorouracil
400 mg m-2 IV bolus, then 5-Fluorouracil 400 mg m-2 by IV
infusion over 22 h in 5% Dextrose. This was repeated over
the next 24 h. The schedule was given every 2 weeks for up
to 12 courses depending upon the response.
Allopurinol mouthwashes (Clark & Slevin, 1985) at a
strength of 1 mg ml-' were used hourly for the first 4 h after
the 5-Fluorouracil bolus and 4-hourly thereafter for 48 h.
The mouthwash was retained in the mouth for 5 min at each
use.
Assessment ofresponse
Measurable lesions were assessed clinically or by ultrasound
or Computed Tomographic scans. These scans were repeated
routinely after 3 months and 6 months treatment, or sooner
if there was other evidence of disease progression on clinical
or biochemical grounds. Standard WHO response criteria
were applied.
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a Toxicity analysis
Patients were questioned by medical staff regarding toxicity
after each cycle of treatment and the replies recorded on
pro-forma sheets in the case notes. Karnofsky scores and
patients' subjective response assessments were recorded sim-
ultaneously.
Results
Response
The overall response rate was 26% (95% confidence interval
15-37%): Two complete responses (One on computed tomo-
graphic scanning, the other on ultrasound) and 14 partial
responses (six on CT scanning, eight on ultrasound) were
seen among 62 evaluable patients. Two patients were lost to
follow up and four patients received the treatment as adju-
vant therapy.
Analysis by primary site shows a response rate in colorec-
tal tumours of 24% (95% CI 11-37%) and in gastric
tumours of 40% (95% CI 10-70%). No responses were seen
in pancreatic tumours. The median duration of remission was
6.4 months and median survival for the whole group 17.3
months.
There was no significant difference in pre-treatment perfor-
mance status between responders and non-responders. Per-
formance status rose following the start of treatment in 60%
of patients, and 70% reported a subjective improvement in
overall well-being.
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Toxicity
Three hundred and eighty-six courses of treatment (median
five per patient) were evaluated for toxicity. No toxicity
greater than WHO Grade II was seen. Nine per cent of
courses were associated with some oral mucositis and 12%
with some diarrhoea. Only nine (3%) treatments were de-
layed by neutropenia (absolute neutrophil count less than
1.5 x 1091-') and no febrile neutropenic episodes occurred.
Forty-six per cent ofpatients reported some nausea and 25%
vomiting, but this was frequently present before the start of
treatment owing to abdominal tumour masses. Anti-emetics
were not prescribed prophylactically solely for chemotherapy.
Six patients developed a hand-foot syndrome during treat-
ment. This was usually seen after at least four cycles of
treatment and responded to pyridoxine at a dose of 150 mg/
day as described in a recent report (Mortimer & Anderson,
1989).
Rates of toxicity using this regimen are compared with
others previously reported in Figure 1.
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Figure 1 Toxicity rates reported previously compared with the
present study. M severe; M mild/moderate; m not stated.
References: 1. Petrelli, 1988 - 5FU by weekly bolus. 2. Petrelli,
1989 5FU by weekly bolus. 3. Poon, 1989 - 5FU daily bolus
I week in 4. 4. Machover, 1986 - 5FU daily bolus 1 week in 4.
5. Erlichman, 1988 - 5FU daily bolus I week in 4.
Discussion
These results confirm that it is possible to give an effective
regimen of 5-fluorouracil and high-dose folinic acid with little
toxicity. Although the dose-intensity of the schedule (800-
mgm-2 week-' of 5-FU) is considerably higher than that
used by others (450-460 mg m2 week-') the frequency with
which diarrhoea and oral mucositis occur are greatly reduced
and myelosuppression is not a problem at all. There was no
necessity for dose reductions and 97% of treatments were
given as planned.
The response rate seen was in accord with those obtained
in other colorectal cancer studies (De Gramont et al., 1988;
Petrelli et al., 1988; Petrelli et al., 1989; Poon et al., 1989;
Machover et al., 1986; Erlichman et al., 1988; Arbuck, 1989),
suggesting similar efficacy, although clearly a phase III trial
would be required to confirm this. The response rate in
gastric cancers is comparable to that described for more toxic
combination regimens (Macdonald et al., 1979; Gastrointes-
tinal Tumor Study Group 1982; Douglass et al., 1984) and
considerably better than that reported previously for 5-
fluourouracil and folinic acid (Arbuck et al., 1987; Berenberg
et al., 1989). Although the numbers treated are small it
certainly appears worthy of further evaluation. The use of
allopurinol mouthwashes in preventing oral mucositis is now
the subject of a randomised trial.
It is clearly of great importance that chemotherapy given
with purely palliative intent should have as few adverse
effects as possible. Although shown to be effective against
colorectal adenocarcinomas the combination of high-dose
folinic acid and 5-fluorouracil has not been widely used up to
now because of previous reports of severe toxicity and only
modest activity in gastric cancers. 5-fluorouracil when given
by infusion is known to be better tolerated than bolus doses,
but the coincident use of folinic acid poses the problem of
obtaining adequate levels of both drugs at the same time.
(An extracellular reduced folate concentration of 10ILmol 1-'
is required for optimal inhibition of thymidylate synthetase
in culture studies (Evans et al., 1981)). A 50% bolus loading
dose of 5-fluorouracil immediately after the folinic acid is
therefore used to produce high levels of the drug coincident
with the highest levels of reduced folate, whilst the following
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infusion maintains their effect. This may be expected to
improve cytotoxicity whilst maintaining tolerability. That
admission to hospital is required for 48 h every fortnight is a
disadvantage, but the lack of toxicity once at home is con-
siderable compensation for this. There are advantages over a
schedule of daily injections for 5 consecutive days which
often necessitates admission to hospital for logistic reasons
such as the distance patients may be obliged to travel. If this
schedule were to be widely adopted consideration could be
given to the use of indwelling venous access devices for the
administration of treatment by portable infusion pumps.
Thus it is felt that this regimen achieves a useful thera-
peutic balance, limiting toxicity but retaining anti-tumour
activity. It should now be evaluated in a phase III trial
against the 'standard' 5-fluorouracil/folinic acid regimens.
The authors wish to thank Dr H. Rees for histological review and
Dr R.H. Reznek, Dr P. Cannon and the department of radiology for
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